Compare Bank of Montreal (BMO) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bank of Montreal vs Moderna, Inc. — how do they compare? Bank of Montreal trades at $180.98 (market cap $125.53B), while Moderna, Inc. trades at $67.28 (market cap $26.76B). The key difference: Bank of Montreal is far larger — about 4.7× Moderna, Inc.'s market cap, and Bank of Montreal pays a 2.74% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| BMO | MRNA | |
|---|---|---|
Market Cap | $125.53B | $26.76B |
Sector | Financials | Health |
52-Week High | $180.86 | $81.80 |
52-Week Low | $110.44 | $22.36 |
Dividend Yield | 2.74% | — |
Enterprise Value | — | $22.85B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BMO trades at $178.69, down 0.15% today, with a bullish technical signal supported by moving averages and key resistance at $180. The company reported strong Q1 2026 earnings of $2.68 per share, beating estimates, and maintains a solid net income margin of 25.92%. Recent acquisitions and dividend increases highlight strategic growth, while analyst sentiment is balanced with 44% buy ratings.
Outlook remains positive driven by consistent earnings beats and expansion in metals & mining banking. Risks include valuation above historical norms with a P/E of 19.48 and exposure to interest rate sensitivity. The stock offers a compelling dividend yield but faces macroeconomic headwinds that could pressure future performance.
Moderna (MRNA) trades at $67.01, down 1.85% today, with a bullish technical signal from moving averages. The company continues to post net losses despite beating EPS estimates in recent quarters, with revenue declining from pandemic peaks. Recent news highlights pipeline expansion into oncology and autoimmune diseases, with an FDA decision on its mRNA flu vaccine expected by August 5, 2026.
While Moderna's pipeline diversification offers long-term growth potential, significant risks remain from persistent negative profitability and high valuation multiples. Analyst consensus is cautious with a $49 price target below current levels, suggesting limited near-term upside despite recent positive developments in vaccine approvals and strategic shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bank of Montreal
Bank of Montreal is a diversified financial-services provider based in North America, operating four business segments: Canadian personal and commercial banking, U.S. P&C banking, wealth management, and capital markets. The bank's operations are primarily in Canada, with a material portion also in the U.S.
Read more on BMO →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
